Details
Stereochemistry | ACHIRAL |
Molecular Formula | NO |
Molecular Weight | 30.0061 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[N]=O
InChI
InChIKey=ODUCDPQEXGNKDN-UHFFFAOYSA-N
InChI=1S/HNO/c1-2/h1H
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24560804
http://www.reading.ac.uk/nitricoxide/intro/no/discovery.htm
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/24560804
http://www.reading.ac.uk/nitricoxide/intro/no/discovery.htm
In mammals Nitric Oxide (NO) is an important cellular signaling molecule involved in many physiological and pathological processes. It is a powerful vasodilator with a short half-life of a few seconds in the blood. Low levels of nitric oxide production are important in protecting organs such as the liver from ischemic damage. Nitric oxide production is associated with nonalcoholic fatty liver disease (NAFLD) and is essential for hepatic lipid metabolism under starvation. Nitric oxide (INOmax) is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which then leads to vasodilation. When inhaled, nitric oxide selectively dilates the pulmonary vasculature, and because of efficient scavenging by hemoglobin, has minimal effect on the systemic vasculature. INOmax appears to increase the partial pressure of arterial oxygen (PaO2) by dilating pulmonary vessels in better-ventilated areas of the lung, redistributing pulmonary blood flow away from lung regions with low ventilation/perfusion (V/Q) ratios toward regions with normal ratios. NO, can be generated in large quantities and has detrimental effects on the CNS. NO has been shown to increase permeability of the BBB, allowing substances to enter into the brain passively. Because of its importance in neuroscience, physiology, and immunology, NO was proclaimed "Molecule of the Year" in 1992. Research into its function led to the 1998 Nobel Prize for discovering the role of nitric oxide as a cardiovascular signaling molecule (Furchgott, Murad and Ignarro).
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11396481
Curator's Comment: NO can be generated in large quantities and has detrimental effects on the CNS. NO has been shown to increase permeability of the BBB, allowing substances to enter into the brain passively.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111348 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24560804 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | INOMAX Approved UseINOmax is a vasodilator indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents. Launch Date9.4582079E11 |
PubMed
Title | Date | PubMed |
---|---|---|
[The effect of nitric oxide administration on pateints with pulmonary hypertension: a dose-response study]. | 1998 Feb |
|
N-Acetyl-cysteine inhibition of encephalomyelitis Theiler's virus-induced nitric oxide and tumour necrosis factor-alpha production by murine astrocyte cultures. | 1999 |
|
Diet-induced protection against lipopolysaccharide includes increased hepatic NO production. | 1999 Apr |
|
Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. | 1999 Apr 15 |
|
Effects of amlodipine on nitric oxide synthase mRNA expression and coronary microcirculation in prolonged nitric oxide blockade-induced hypertensive rats. | 1999 Aug |
|
Increased vulnerability of neuronal cell lines to sodium nitroprusside-mediated toxicity is caused by the decreased level of nitric oxide metabolites. | 1999 Aug-Oct |
|
Endogenous endothelial cell nitric-oxide synthase modulates apoptosis in cultured breast cancer cells and is transcriptionally regulated by p53. | 1999 Dec 31 |
|
Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. | 1999 Feb |
|
Systemic hypotension on withdrawal from inhaled nitric oxide in an adult patient with acute respiratory distress syndrome. | 1999 Feb |
|
Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. | 1999 Jul |
|
Aortic connexin43 is decreased during hypertension induced by inhibition of nitric oxide synthase. | 1999 Jul |
|
Critical role of sulfenic acid formation of thiols in the inactivation of glyceraldehyde-3-phosphate dehydrogenase by nitric oxide. | 1999 Jul 1 |
|
Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. | 1999 Jun 11 |
|
Nitric oxide, superoxide radicals and mast cells in pathogenesis of indomethacin-induced small intestinal lesions in rats. | 1999 Mar |
|
Modifications induced by LDL from type 1 diabetic patients on endothelial cells obtained from human umbilical vein. | 1999 Nov |
|
Beta2-adrenergic receptor stimulation inhibits nitric oxide generation by Mycobacterium avium infected macrophages. | 1999 Nov 1 |
|
Nitric oxide induces Zn2+ release from metallothionein by destroying zinc-sulphur clusters without concomitant formation of S-nitrosothiol. | 1999 Nov 15 |
|
Nitric oxide inhalation inhibits pulmonary apoptosis but not inflammatory injury in porcine meconium aspiration. | 1999 Oct |
|
Vascular effects of endothelin-1 in essential hypertension: relationship with cyclooxygenase-derived endothelium-dependent contracting factors and nitric oxide. | 2000 |
|
The potential role of nitric oxide in the hypertrophic growth of the left ventricle. | 2000 |
|
Nitric oxide-compromised hypertension: facts and enigmas. | 2000 |
|
Nociceptin receptor activation produces nitric oxide-mediated systemic hypotension. | 2000 |
|
Angiotensin in the nucleus tractus solitarii contributes to neurogenic hypertension caused by chronic nitric oxide synthase inhibition. | 2000 Aug |
|
Nitric oxide induces thymocyte apoptosis via a caspase-1-dependent mechanism. | 2000 Aug 1 |
|
Copper-dependent formation of disulfide-linked dimer of S100B protein. | 2000 Feb 15 |
|
Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. | 2000 Jan |
|
Nitric oxide synthase inhibitors attenuate ozone-induced airway inflammation in guinea pigs. Possible role of interleukin-8. | 2000 Jan |
|
Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice. | 2000 Jan 1 |
|
Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. | 2000 Jul |
|
Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). | 2000 Jul |
|
Acetaminophen inhibits iNOS gene expression in RAW 264.7 macrophages: differential regulation of NF-kappaB by acetaminophen and salicylates. | 2000 Jun 16 |
|
Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. | 2000 May 9 |
|
Inhibition of nitric oxide synthase enhances the myocardial toxicity of phenylpropanolamine. | 2000 Nov |
|
Role of nitric oxide in adrenocorticotrophin-induced hypertension: L-arginine effects reversed by N-nitro-L-arginine. | 2000 Nov |
|
Female sex steroids: effects upon microglial cell activation. | 2000 Nov 1 |
|
Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. | 2000 Nov 15 |
|
Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. | 2000 Nov 7 |
|
High-calcium diet enhances vasorelaxation in nitric oxide-deficient hypertension. | 2000 Sep |
|
Nitric oxide-induced headache in patients with chronic tension-type headache. | 2000 Sep |
|
Regulation of diaphragmatic nitric oxide synthase expression during hypobaric hypoxia. | 2000 Sep |
|
Lipopolysaccharide and interferon-gamma-induced nitric oxide production and protein oxidation in mouse peritoneal macrophages are affected by glutathione peroxidase-1 gene knockout. | 2001 Aug 15 |
|
Role for endothelin-1-induced superoxide and peroxynitrite production in rebound pulmonary hypertension associated with inhaled nitric oxide therapy. | 2001 Aug 17 |
|
The phosphodiesterase inhibitors pentoxifylline and rolipram suppress macrophage activation and nitric oxide production in vitro and in vivo. | 2001 Feb |
|
15-Deoxy-delta12,14-PGJ2, but not troglitazone, modulates IL-1beta effects in human chondrocytes by inhibiting NF-kappaB and AP-1 activation pathways. | 2001 Jul 13 |
|
Effects of Ginkgo biloba extract (EGb 761) and quercetin on lipopolysaccharide-induced release of nitric oxide. | 2001 Jul 31 |
|
Prostaglandins and nitric oxide mediate superoxide-induced myocardial contractile dysfunction in isolated rat hearts. | 2001 Jun |
|
Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache. | 2001 Mar |
Patents
Sample Use Guides
20 ppm, maintained for up to 14 days or until the underlying oxygen desaturation has resolved
Route of Administration:
Respiratory
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14711563
Curator's Comment: In epithelial cells, NO increased apoptosis by 2.1 +/- 0.2-fold, augmented mRNA expression of Bax, and reduced expression of Bcl-2 compared with basal cultures. In stromal cells, NO increased cell proliferation in a dose-dependent manner, an effect that was blocked by a NO synthase inhibitor.
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
603917
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
EU-Orphan Drug |
EU/3/15/1484
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
340811
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
368512
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
265708
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
551716
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
LOINC |
74369-0
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
NDF-RT |
N0000175940
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
192104
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
756820
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
638918
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
WHO-VATC |
QR07AX01
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
74493
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
621517
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
443914
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
551616
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
CFR |
21 CFR 862.3080
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
NCI_THESAURUS |
C687
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
90595
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
193304
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
INOMAX (AUTHORIZED: RESPITORY INSUFFICIENCY, HYPERTENSION, PULMONARY)
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
FDA ORPHAN DRUG |
403613
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
NDF-RT |
N0000009909
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
WHO-ATC |
R07AX01
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
||
|
DSLD |
1699 (Number of products:1)
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12540MIG
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
Nitric Oxide
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
M7934
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | Merck Index | ||
|
7442
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | RxNorm | ||
|
1246
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
DB00435
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
C695
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
10102-43-9
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
31C4KY9ESH
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
KK-93
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
1948
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
CHEMBL1200689
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
DTXSID1020938
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
2509
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
233-271-0
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
NITRIC OXIDE
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
145068
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
SUB03447MIG
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
16480
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
D009569
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY | |||
|
31C4KY9ESH
Created by
admin on Fri Dec 16 18:35:45 UTC 2022 , Edited by admin on Fri Dec 16 18:35:45 UTC 2022
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)
PRODRUG (METABOLITE ACTIVE)